February 25, 2003

BATTELLEPHARMA ANNOUNCES ADDITION OF DR. JOHN W. MORGAN, VICE PRESIDENT, REGULATORY AND CLINICAL AFFAIRS

BattellePharma Media Contact:
Christy Polsley-Finch
(614) 340-2361
finch@battellepharma.com

COLUMBUS, Ohio - BattellePharma, a privately-held specialty pharmaceutical company, announced today that John W. Morgan, Ph.D., will join the BattellePharma executive team as Vice President, Regulatory and Clinical Affairs.

Morgan, who most recently held the position of Director, Project and Portfolio Management for GlaxoSmithKline brings over 14 years' experience in pharmaceutical drug development to BattellePharma, the majority of which specialized in the area of inhaled respiratory products. His responsibilities included leadership roles in regulatory affairs and project management for metered dose and dry powder inhaler development programs including Serevent® and Ventolin®.

"John Morgan is an outstanding addition to our BattellePharma team," said Chuck Bramlage, BattellePharma President and CEO. "John's expertise in the inhaled respiratory field and his proven record of accomplishment of global development programs leading to NDA approvals will be a tremendous asset to us. We are excited to be able to add significant depth to our management team as a result of last week's announcement of our $22 million private equity Series B fund raise."

"I'm very pleased to join BattellePharma and look forward to contributing to the successful development of BattellePharma's technologies for inhaled drug delivery," stated John Morgan.

Morgan holds a B.A. Degree in Chemistry from Indiana University and a Ph.D. in Organic Chemistry from Princeton University. Following completion of a post-doctoral appointment at Johns Hopkins University, Dr. Morgan joined Proctor and Gamble where he served in roles of research, development and regulatory affairs. In 1994, Dr. Morgan joined GlaxoSmithKline as Associate Director and was later appointed to Director, Regulatory Affairs. Morgan has also served in several capacities in the Regulatory Affairs Professional Society, most recently as Member of the Society's Board of Directors.

About BattellePharma

BattellePharma is a privately-held specialty pharmaceutical company leveraging science and technology to design more effective medicines. BattellePharma's products are based on two platform technologies: Mystic inhalation technology and novel formulation technologies. The company develops products by combining these platforms with novel or generic compounds to create therapies to treat respiratory and systemic diseases. BattellePharma's MysticTM technology is expected to set a new standard for inhaled drug delivery in the 21st century. BattellePharma has partnerships with numerous pharmaceutical corporations including Abbott Laboratories, Corus Pharma Inc., GlaxoSmithKline, Pfizer Inc., Pharmacia Corporation, and VIASYS Healthcare GmbH. For more information on BattellePharma, reference the company's website at www.battellepharma.com.